Cerus CorpNASDAQ:CERS
- LAST PRICE1.7050
- TODAY'S CHANGE (%)-0.0150 (-0.8721%)
- Bid / Lots1.7000/ 11
- Ask / Lots1.7100/ 50
- Open / Previous Close1.7300 / 1.7200
- Day Range
- 52 Week Range
- Volume224,083
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | CERS |
|---|---|---|
| 09:32 ET | 8175 | 1.7 |
| 09:33 ET | 4200 | 1.715 |
| 09:35 ET | 1050 | 1.725 |
| 09:37 ET | 20095 | 1.73 |
| 09:39 ET | 600 | 1.725 |
| 09:42 ET | 741 | 1.72 |
| 09:44 ET | 13665 | 1.705 |
| 09:46 ET | 621 | 1.705 |
| 09:48 ET | 522 | 1.705 |
| 09:50 ET | 350 | 1.705 |
| 09:51 ET | 100 | 1.705 |
| 09:53 ET | 600 | 1.705 |
| 09:55 ET | 700 | 1.705 |
| 09:57 ET | 2006 | 1.695 |
| 10:00 ET | 200 | 1.695 |
| 10:02 ET | 1840 | 1.7 |
| 10:04 ET | 300 | 1.7 |
| 10:06 ET | 3960 | 1.71 |
| 10:08 ET | 2383 | 1.715 |
| 10:09 ET | 391 | 1.715 |
| 10:11 ET | 100 | 1.715 |
| 10:13 ET | 300 | 1.72 |
| 10:15 ET | 100 | 1.715 |
| 10:18 ET | 1400 | 1.715 |
| 10:20 ET | 3000 | 1.725 |
| 10:22 ET | 12171 | 1.725 |
| 10:24 ET | 8313 | 1.74 |
| 10:26 ET | 20121 | 1.725 |
| 10:27 ET | 14471 | 1.73 |
| 10:29 ET | 864 | 1.73 |
| 10:31 ET | 6284 | 1.734 |
| 10:33 ET | 4500 | 1.735 |
| 10:36 ET | 1500 | 1.735 |
| 10:38 ET | 2284 | 1.74 |
| 10:40 ET | 4481 | 1.74 |
| 10:42 ET | 5512 | 1.735 |
| 10:44 ET | 4010 | 1.745 |
| 10:45 ET | 13156 | 1.74 |
| 10:47 ET | 1446 | 1.735 |
| 10:49 ET | 704 | 1.7375 |
| 10:51 ET | 100 | 1.735 |
| 10:54 ET | 700 | 1.735 |
| 10:56 ET | 817 | 1.73 |
| 10:58 ET | 918 | 1.73 |
| 11:00 ET | 4060 | 1.73 |
| 11:02 ET | 100 | 1.72 |
| 11:03 ET | 100 | 1.725 |
| 11:05 ET | 8057 | 1.72 |
| 11:07 ET | 2300 | 1.7207 |
| 11:09 ET | 6810 | 1.72 |
| 11:12 ET | 1065 | 1.715 |
| 11:14 ET | 800 | 1.715 |
| 11:16 ET | 4937 | 1.72 |
| 11:18 ET | 1274 | 1.725 |
| 11:20 ET | 242 | 1.72 |
| 11:21 ET | 200 | 1.725 |
| 11:23 ET | 100 | 1.725 |
| 11:25 ET | 100 | 1.72 |
| 11:27 ET | 400 | 1.72 |
| 11:30 ET | 2745 | 1.72 |
| 11:32 ET | 200 | 1.715 |
| 11:34 ET | 100 | 1.715 |
| 11:36 ET | 3299 | 1.71 |
| 11:38 ET | 700 | 1.705 |
| 11:39 ET | 2580 | 1.7 |
| 11:41 ET | 100 | 1.705 |
| 11:43 ET | 647 | 1.705 |
Nov 13, 2024
Cerus Corporation to Participate in Upcoming Investor Conferences, from 8:30AM ET on Wednesday Nov 13, 2024 by Dow Jones
8:30AM ET on Wednesday Nov 13, 2024 by Dow Jones
Oct 30, 2024
Cerus Corporation Announces Third Quarter 2024 Financial Results, from 4:00PM ET on Wednesday Oct 30, 2024 by Dow Jones
4:00PM ET on Wednesday Oct 30, 2024 by Dow Jones*DJ Cerus 3Q Loss/Shr 2c >CERS, from 4:00PM ET on Wednesday Oct 30, 2024 by Dow Jones
4:00PM ET on Wednesday Oct 30, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Cerus Corp | 319.4M | -15.9x | --- |
Anika Therapeutics Inc | 252.6M | -2.6x | --- |
Semler Scientific Inc | 323.2M | 25.6x | +31.99% |
Tactile Systems Technology Inc | 375.8M | 24.6x | +29.16% |
Alpha Teknova Inc | 315.0M | -8.2x | --- |
Treace Medical Concepts Inc | 474.1M | -7.6x | --- |
Company Information
Cerus Corporation is a biomedical products company. The Company is focused on developing and commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT Blood System, which is based on its proprietary technology for controlling biological replication, is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. Its INTERCEPT Blood System is intended for use with blood components and certain of their derivatives: platelets, plasma, red blood cells and to produce INTERCEPT Fibrinogen Complex (IFC), and pathogen reduced plasma, cryoprecipitate reduced. The INTERCEPT Blood System for Cryoprecipitation uses its plasma system to produce IFC for the treatment and control of bleeding, including massive hemorrhage, associated with fibrinogen deficiency. In addition, the INTERCEPT Blood System for Cryoprecipitation is used to produce pathogen reduced plasma, cryoprecipitate reduced.
Contact Information
- Headquarters
- 1220 Concord AvenueCONCORD, CA, United States 94520
- Phone
- 925-288-6000
- Fax
- 925-288-6001
Executives
- Independent Chairman of the Board
- Daniel Swisher
- President, Chief Executive Officer, Director
- William Greenman
- Chief Financial Officer, Vice President - Finance
- Kevin Green
- Chief Operating Officer
- Vivek Jayaraman
- Chief Human Resource Officer
- Alicia Goodman
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $319.4M |
|---|---|
Revenue (TTM) | $197.9M |
Shares Outstanding | 185.7M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 1.21 |
EPS | $-0.11 |
Book Value | $0.29 |
P/E Ratio | -15.9x |
Price/Sales (TTM) | 1.6 |
Price/Cash Flow (TTM) | --- |
Operating Margin | -5.96% |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
